枸橼酸芬太尼(Fentanyl Citrate) - 药物靶点：μ opioid receptor_在研适应症：突出痛，癌症疼痛，妊娠剧吐_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Abstral Sublingual、E-Fen Buccal、Fentanyl citrate (JP17/USP)

+ [33]

靶点

μ opioid receptor

作用方式

激动剂

作用机制

μ opioid receptor激动剂(μ-阿片受体激动剂)

治疗领域

神经系统疾病泌尿生殖系统疾病其他疾病

在研适应症

突出痛癌症疼痛妊娠剧吐+ [1]

非在研适应症

镰状细胞血症烧伤慢性疼痛+ [9]

原研机构

Rising Pharmaceuticals, Inc.

在研机构

Grünenthal GmbH

Kyowa Kirin Co., Ltd.

Istituto Gentili Srl

+ [5]

非在研机构

Kyowa Kirin Services Ltd.Teva Branded Pharmaceutical Products R&D, Inc.

Cephalon, Inc.

+ [6]

权益机构

Kunwha Pharmaceutical Co., Ltd.

Daiichi Sankyo Co., Ltd.

Collegium Pharmaceutical, Inc.

+ [7]

最高研发阶段批准上市

首次获批日期

美国 (1968-02-19),

麻醉

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C28H36N2O8

InChIKeyIVLVTNPOHDFFCJ-UHFFFAOYSA-N

CAS号990-73-8

关联

1,089

项与枸橼酸芬太尼相关的临床试验

NCT07214714

/ Not yet recruiting临床4期IIT

Hemodynamic and Cardiac Effects of Dexmedetomidine Versus Fentanyl by Intravenous Infusion as Adjuncts to General Anesthesia in Patients Undergoing Major Abdominal Cancer Surgeries.

________________________________________
Background :
Major abdominal cancer surgery is among the most invasive procedures, often associated with extensive tissue damage, severe postoperative pain, and delayed recovery. Inadequate pain management can result in adverse physiological responses such as tachycardia, hypertension, prolonged immobility, and extended hospital stay. Moreover, poorly controlled pain may impair immune function and contribute to neuroendocrine, metabolic, gastrointestinal, and cardiopulmonary complications. Therefore, effective analgesia is essential to improve patient outcomes and recovery.
Multimodal analgesia has emerged as the gold standard for managing postoperative pain in major abdominal surgery. It integrates regional techniques (such as epidural or intrathecal analgesia), peripheral nerve blocks (e.g., transversus abdominis plane block), systemic opioids, and non-opioid agents including NSAIDs and acetaminophen. This approach minimizes surgical stress, maintains hemodynamic stability, and facilitates early ambulation and discharge.
Opioids, particularly fentanyl, are widely used as intrathecal adjuvants due to their rapid onset and favorable analgesic profile. However, selective alpha-2 adrenergic receptor agonists such as clonidine and dexmedetomidine are gaining attention for their sedative, analgesic, sympatholytic, and hemodynamic-stabilizing effects. Administered intrathecally, epidurally, or intravenously, they can enhance analgesia while reducing anesthetic requirements without causing profound sedation.
Conventional monitoring with heart rate and non-invasive blood pressure may overlook subtle variations in cardiac output. Electrical cardiometry (ICON®) provides continuous, non-invasive, beat-to-beat measurement of cardiac parameters and has been validated across different patient groups. Accordingly, the present study aims to compare intravenous dexmedetomidine and fentanyl as adjuvants to general anesthesia, focusing on their effects on hemodynamics and cardiac function in major abdominal cancer surgery using electrical cardiometry.

开始日期2025-11-01

申办/合作机构

Assiut University

NCT07091123

/ Recruiting临床4期IIT

Patient Preference and Long-term Outcomes in Persistent Spinal Pain Syndrome: A Prospective Study Comparing Spinal Cord Stimulation to Intrathecal Drug Delivery.

Spinal cord stimulation (SCS) or intrathecal drug delivery (pain pump) can be effective in providing pain relief for patients with low back pain who have not responded to other treatments. While both treatments, SCS and pain pump, may help with low back pain relief, it is not known which treatment may work better for patients. SCS and pain pumps involve an implanted device in the body.
In this study, we are asking patients to undergo a trial of both treatment modalities, SCS and pain pump, as screening tests prior to considering an implant. A total of 36 patients will be enrolled in this study. After both trials are completed, participants will be seen in the office and asked which treatment modality they believe has been more effective for relieving pain during the trial periods by completing questionnaires. If neither treatment was effective in improving baseline pain by at least 50%, participants would not qualify for either implant whether or not they are part of this study. Direct study participation would end here. If either or both treatment modalities improved baseline pain by at least 50%, participants will be asked to choose the treatment that worked better: SCS or pain pump. Participants will then have the option to proceed to the permanent implant of choice: SCS or pain pump. Direct study participation would end here but participants will then be followed in the doctor's office after implant as is customary for usual clinical care. The study data collection will conclude when the screening tests are completed.

开始日期2025-10-13

申办/合作机构

University Hospitals Cleveland Medical Center

NCT07112430

/ Not yet recruiting临床1/2期IIT

Intranasal Fentanyl to Reduce Pain Intensity Associated With Retinopathy of Prematurity Screening in Preterm Infants: A Randomized Control Trial

This single-center, double-blinded, randomized controlled trial aims to evaluate the efficacy and safety of intranasal fentanyl (INF) for reducing pain during retinopathy of prematurity (ROP) screening in preterm infants. The trial will enroll preterm neonates (≤32 weeks gestation) requiring ROP screening and randomize them to receive either intranasal fentanyl (2 mcg/kg) or a placebo (normal saline) 5-10 minutes prior to the procedure. The primary outcome is pain intensity measured using the Premature Infant Pain Profile-Revised (PIPP-R) at 30 seconds after speculum insertion. Secondary outcomes include physiological (heart rate, oxygen saturation), behavioral (crying time), and recovery indicators, along with adverse events and need for rescue dosing. This study addresses a critical gap in evidence by exploring a non-invasive pharmacologic intervention for procedural pain in the neonatal intensive care unit (NICU) setting. The findings may inform future practice and guidelines for neonatal pain management.

开始日期2025-10-01

申办/合作机构

IWK Health Centre

[+1]

100 项与枸橼酸芬太尼相关的临床结果

登录后查看更多信息

100 项与枸橼酸芬太尼相关的转化医学

登录后查看更多信息

100 项与枸橼酸芬太尼相关的专利（医药）

登录后查看更多信息

8,530

项与枸橼酸芬太尼相关的文献（医药）

2025-11-01·BRITISH JOURNAL OF ANAESTHESIA

Impact of neuromuscular block monitoring and reversal on postoperative pulmonary complications in thoracic surgery: a Bayesian analysis of the iPROVE-OLV trial

Article

BACKGROUND:

Postoperative pulmonary complications (PPCs) are a significant concern in thoracic surgery. A modifiable factor influencing PPCs is postoperative residual neuromuscular block (NMB), which impairs respiratory muscle function.

METHODS:

We performed a post hoc Bayesian analysis of data from the iPROVE-OLV study, a multicentre randomised controlled trial involving patients undergoing thoracic surgery with one-lung ventilation. We compared participants managed with any neuromuscular monitoring and any reversal vs those managed without either. The primary outcome was the occurrence of a composite of PPCs within the first 7 postoperative days.

RESULTS:

Of the 698 patients included, 657 received any neuromuscular monitoring and any reversal, while 41 did not. Patients managed with any neuromuscular monitoring and any reversal had a lower incidence of PPCs (20%) compared with those without either (34%). Bayesian random effect logistic regression indicated that the use of any neuromuscular monitoring and any reversal reduced PPCs with an odds ratio (OR) ranging from 0.67 (95% credibility interval, CrI, 0.39-1.11) to 0.84 (95% CrI 0.48-1.37), depending on the prior model used. The probability of benefit (OR <1) was between 77% and 94%. Subgroup analysis indicated that sugammadex was more effective than neostigmine in reducing PPCs, with a high probability of benefit (97%), and both neuromuscular monitoring and reversal reduced PCCs when evaluated separately with a high probability of benefit.

CONCLUSION:

Utilising neuromuscular monitoring and reversal agents significantly reduced the risk of PPCs in thoracic surgery. Sugammadex was more efficacious in reducing PPCs compared with neostigmine. These findings support the combined use of neuromuscular monitoring and reversal drugs.

CLINICAL TRIAL REGISTRATION:

NCT03182062.

2025-11-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

A novel label-free carbon dots-based fluorescent aptamer sensor for the detection of fentanyl

Article

作者: Tong, Yishuo ; Yan, Jiangwei ; Niu, Weifen ; Wang, Zheyu ; Liu, Baihui ; Dong, Chuan

Fentanyl, a widely abused potent synthetic opioid, poses a challenge due to its narrow therapeutic window, increasing the risk of overdose and death. Fast, easy, and cost-effective screening for fentanyl in biological samples is crucial for forensic and public safety purposes. We hereby present a label-free fluorescence sensor for the precise and sensitive identification of fentanyl, utilizing carbon dots (CDs) in conjunction with aptamers. By synthesizing green-emitting CDs in a single step using an environmentally friendly method with o-phenylenediamine (OPD) and thiourea in acetone, the CDs displayed excellent optical properties and biocompatibility. Due to the positive charge of CDs, their fluorescence quenching is caused by electrostatic interactions with negatively charged aptamers. When fentanyl is introduced, the specific binding between fentanyl and the fentanyl aptamer is strengthened, resulting in fluorescence recovery. Under optimal experimental conditions, there was a linear relationship between fluorescence intensity and fentanyl concentration in the 5-1000 nM with a limit of determination of 1.90 nM. The robust quantification of fentanyl in complex human saliva matrices achieved by this aptamer-based biosensing platform validates its clinical reliability, particularly for non-invasive point-of-care monitoring and harm-reduction interventions in opioid crisis management.

2025-10-03·The International journal of neuroscience

The effects of combined acupuncture anesthesia and serratus anterior plane block with ropivacaine on postoperative analgesia in patients undergoing chest surgery

Article

作者: Wu, Zhen ; Wang, Jieqiong ; Wang, Chunfeng ; Shi, Lingyan ; Yu, Xiangyuan ; Cai, Hongqin

OBJECTIVE:

To investigate the effects of combined acupuncture anesthesia and ropivacaine on postoperative analgesia and neuro-related factors in patients undergoing chest surgery.

METHODS:

The analgesic drug dosage, postoperative PCIA pressing times, VAS scores at rest and during activity at 6 h (T1), 12 h (T2), 18 h (T3), and 24 h (T4) postoperatively.

RESULTS:

The analgesic drug dosage and postoperative PCIA pressing times were lower in the observation group than in the control group (p < 0.05). The VAS scores at T1-T4 postoperatively were lower in the observation group than in the control group (p < 0.05). The SAS scores at T1-T4 postoperatively were lower in the observation group than in the control group (p < 0.05). The levels of IL-6 and IL-10 on postoperative day 1 were higher than those on preoperative day 1 in both groups, with a smaller change in the observation group (p < 0.05). The levels of S100β protein on postoperative day 1 were higher than those on preoperative day 1 in both groups, while the BDNF levels were lower, with a smaller change in the observation group (p < 0.05). There was no significant difference in the incidence of adverse reactions between the control group (11.36%) and the observation group (15.56%) (p > 0.05).

CONCLUSION:

Combined acupuncture anesthesia and ropivacaine can effectively improve postoperative analgesia and agitation in patients undergoing chest surgery, reduce the dosage of analgesic drugs, regulate the levels of inflammatory factors and neurotrophic factors in patients, and do not increase the risk of adverse reactions related to patients.

71

项与枸橼酸芬太尼相关的新闻（医药）

2025-10-29

·PRNewswire

CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model

SEATTLE, Oct. 29, 2025 /PRNewswire/ -- CounterX Therapeutics, Inc., a biotechnology company focused on developing novel antibody therapeutics and vaccines to address opioid overdose and dependence, today announced the publication of its latest peer-reviewed preclinical study in The Journal of Pharmacology and Experimental Therapeutics. The study highlights the potential of CTRX-101, CounterX Therapeutics' proprietary anti-fentanyl monoclonal antibody, to rapidly reverse life-threatening respiratory depression caused by exposure to fentanyl and its analogs. Conducted in a translational preclinical model, the study demonstrates that administration of the CTRX-101 effectively restores normal breathing following fentanyl overdose. Fentanyl overdose is the leading cause of death for Americans aged 18 – 45. Fentanyl overdoses result in approximately 50,000 deaths and more than 700,000 emergency department visits each year. CTRX-101 is being developed for the prevention and treatment of fentanyl overdose in patients with moderate to severe opioid use disorder (OUD). "These findings provide strong supporting evidence for the clinical development of CTRX-101 to address lethal overdoses with fentanyl," said Dr. Marco Pravetoni, Founder and Chief Scientific Officer at CounterX Therapeutics. "Unlike existing therapies that rely on opioid receptor blockade, CTRX-101 binds to fentanyl, sequesters it in the bloodstream, and prevents its lethal effects on the brain and respiratory system." The publication reinforces CounterX Therapeutics' leadership in developing novel therapies and builds on previous preclinical studies of CTRX-101 that demonstrate efficacy, selectivity, and safety for the prevention and treatment of acute fentanyl overdose. "This exciting study marks a key milestone in translating products developed with our CounterXL™ Platform from preclinical models to potential human application," said Dr. Shawn Iadonato, Chief Executive Officer at CounterX Therapeutics. "We believe CTRX-101 has the potential to provide a differentiated pre-exposure prophylaxis treatment for fentanyl and complement current standards of care in opioid use disorders." The full article is available for viewing under Publications section of the company's website at . About CounterX Therapeutics CounterX Therapeutics is at the forefront of the battle against the opioid epidemic, exploiting cutting-edge biotechnology to develop life-saving therapeutics and vaccines. We combine scientific expertise with an experienced leadership team and a deep commitment to social impact. Our groundbreaking antibody therapies are designed to blunt the effects of opioids, reduce the risk of overdose and a provide a path to recovery. Additionally, our pioneering vaccine technology aims to prevent addiction relapse by blocking the euphoric effects of opioids, empowering individuals to maintain a long-term recovery. Dr. Marco Pravetoni is the Founder and Chief Scientific Officer at CounterX Therapeutics and Professor of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine. CTRX-101: CTRX-101, is a monoclonal antibody against fentanyl that is in development for the prevention of accidental overdose in high-risk patients. It is a long-acting subcutaneous injectable product that is not an opioid or controlled substance. CTRX-101 was well-tolerated in preclinical models with no serious adverse events when used in combination with other medications for opioid use disorder (OUD). It is not expected to cause opioid withdrawal and may be safe when used in combination with other medications. FOR FURTHER INFORMATION, PLEASE CONTACT: CounterX Therapeutics Jacques Bouchy Chief Business Officer 206.486.4755 [email protected] SOURCE CounterX Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

疫苗

2025-10-23

·FiercePharma

FDA cites Nephron again for ongoing issues the generics manufacturer has failed to resolve

Generics contract manufacturer Nephron Pharmaceuticals is in hot water again with the FDA after an August inspection of its facility in South Carolina turned up several issues that have been ongoing for the last few years. Three years ago, the FDA found so many violations at a Nephron Pharmaceuticals manufacturing facility that the U.S. regulator admitted in a warning letter the issues were so numerous they couldn’t all be documented.Fast-forward to this year, and the plant in West Columbia, South Carolina, is still running afoul of the FDA. In a recent Form 483 report, the agency cited several problems that were evident in an August inspection of the facility. Most of the observations were repeat issues identified in Nephron's previous interactions with the agency.Most notably, the report identified a lack of procedures to prevent contamination of manufactured products. The procedures are “not established and written,” the FDA said.“These repeated and systemic lapses demonstrate that your firm has not implemented or enforced adequate aseptic practices to maintain sterility assurance of drug products,” the inspectors wrote.The inspectors identified a laundry list of sterility issues, including operators failing to wash their hands or to clean IV bags. Trash removal was conducted while filling operations were in progress. Doors to manufacturing rooms were left open during aseptic operations. Sanitizing wipes that are designed for single use were reused after being left on shelves. The report also specified a variety of airflow problems.The regulator added that the overall lack of procedures to prevent microbial contamination was a “repeated observation” from inspections performed in 2023 and 2024.The company did not immediately respond to a request for comment.Nephron is a privately owned contract manufacturer of generic respiratory medications. It also serves as a 503B outsourcing facility, producing medications for U.S. hospitals that are in shortage. The company specializes in blow-fill-seal production. The technology is designed to allow medications to be formed, filled and sealed in a continuous process without human intervention in a sterile, closed area. In its write-up, the FDA further noted Nephron’s system for monitoring environmental conditions was lacking and that the company had not established an environmental monitoring program. This also was a repeated observation from a 2024 report of an inspection of the plant.The inspectors also found deficiencies in alarm management, with employees disregarding alerts designed to maintain aseptic conditions. This also was a repeated observation from a 2024 inspection.“These deficiencies in alarm management and oversight create an unacceptable risk of microbial ingress and contamination of sterile products.” the FDA wrote.Additionally, Nephron failed to establish adequate written procedures for production and process controls designed to assure drug products meet strength, purity and quality specifications, according to the FDA.Nephron has previously run afoul of the FDA. In 2013, the company was cited for its marketing of an over-the-counter asthma medication. Two years later, the company recalled 80,000 cartons of the drug over discoloration issues. In 2022, Nephron came under intense scrutiny when it recalled more than 2 million drug doses—covering a wide variety of products including sodium bicarbonate injections, ephedrine injections and fentanyl citrate bags—because of sterility concerns. In an exhaustive warning letter that year, the FDA identified several of the same issues raised in the most recent report.

2025-10-23

·蒲公英Ouryao

参比制剂（第97批）名单发布

转自：国家药监局编辑：随风 2025年10月23日，国家药监局发布了第97批次仿制药一致性评价参比制剂目录，新增品种33个。经国家药品监督管理局仿制药质量和疗效一致性评价专家委员会审核确定，现发布仿制药参比制剂目录（第九十七批），特此通告。新增品种：注射用盐酸依拉环素、索吡溴铵凝胶、盐酸奥昔布宁洗剂、甲苯磺酸纳地美定片、富马酸比索洛尔口服溶液、鬼臼毒素溶液、亚硒酸注射液、布地奈德肠溶胶囊、盐酸氨溴索口服溶液、他氟噻吗滴眼液、贝派度酸依折麦布片、中性腹膜透析液（乳酸盐）、中性低钙腹膜透析液（乳酸盐）、克霉唑阴道片、酚咖片、壬二酸凝胶、洛度沙胺氨丁三醇滴眼液、盐酸罗匹尼罗片、醋酸兰瑞肽缓释注射液（预充式）、雌二醇凝胶、磷酸芦可替尼片、枸橼酸芬太尼注射液、酒石酸唑吡坦片、盐酸美西律片、米诺地尔搽剂、马来酸甲麦角新碱注射液、盐酸齐拉西酮胶囊等；仿制药参比制剂目录（第97批）

一致性评价

100 项与枸橼酸芬太尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01399	枸橼酸芬太尼	N02AB03 N01AH01	DB00813

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
疼痛	美国	Adalvo Ltd.	2009-07-16
突出痛	欧盟	Teva Pharmaceuticals Europe BV	2008-04-04
突出痛	冰岛	Teva Pharmaceuticals Europe BV	2008-04-04
突出痛	列支敦士登	Teva Pharmaceuticals Europe BV	2008-04-04
突出痛	挪威	Teva Pharmaceuticals Europe BV	2008-04-04
癌症疼痛	美国	Cephalon, Inc.	1998-11-04
妊娠剧吐	中国	宜昌人福药业有限责任公司	1981-01-01
麻醉	美国	Rising Pharmaceuticals, Inc.	1968-02-19

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
头颈部肿瘤	临床3期	意大利	L. Molteni & C. dei F.lli Alitti Società di Esercizio SpA	2014-09-01
呼吸功能不全	临床3期	-	BioDelivery Sciences International, Inc.	2008-06-01
慢性疼痛	临床3期	美国	Cephalon, Inc.	2006-12-01
复杂性局部疼痛综合征	临床3期	美国	Cephalon, Inc.	2005-09-01
腰痛	临床3期	美国	Cephalon, Inc.	2005-09-01
神经痛	临床3期	美国	Cephalon, Inc.	2005-09-01
疱疹后神经痛	临床3期	美国	Cephalon, Inc.	2005-09-01
肿瘤	临床3期	-	Cephalon, Inc.	2004-06-01
阵发性呼吸困难	临床2期	德国	Teva Branded Pharmaceutical Products R&D, Inc.	2013-03-01
肺癌	临床2期	德国	Teva Branded Pharmaceutical Products R&D, Inc.	2013-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04230681 (CTgov)	早期临床1期	阻塞性睡眠呼吸暂停综合征 \| 扁桃体炎	189	Hydromorphone (Hydromorphone)	網遞簾簾餘艱顧鹹淵觸 = 衊窪衊鹽鹽餘顧積顧鹽憲獵製廠憲鹹鹽糧選蓋 (願鏇網衊鹽顧壓膚鏇範, 夢範廠襯衊醖淵廠獵積 ~ 膚築齋築餘餘餘願夢齋) 更多	-	2024-12-18
				Fentanyl (Fentanyl)	網遞簾簾餘艱顧鹹淵觸 = 構糧構齋醖範範壓艱糧憲獵製廠憲鹹鹽糧選蓋 (願鏇網衊鹽顧壓膚鏇範, 夢窪網艱製餘淵選鹹觸 ~ 鹽膚獵衊網蓋齋廠膚築) 更多
WCLC2024 人工标引	临床3期	镇静	84	Midazolam with Fentanyl	網膚夢窪鏇廠衊簾繭製(鏇膚鬱觸願襯窪襯構艱) = 製繭鑰夢鹽鹹淵餘衊糧網夢繭簾齋願簾衊艱願 (膚鏇壓廠網鹽壓糧鬱顧 ) 更多	积极	2024-09-07
				Midazolam with Placebo	網膚夢窪鏇廠衊簾繭製(鏇膚鬱觸願襯窪襯構艱) = 醖廠艱糧鏇餘鬱窪鹹積網夢繭簾齋願簾衊艱願 (膚鏇壓廠網鹽壓糧鬱顧 ) 更多
NCT03435003 (CTgov)	临床4期	术后恶心呕吐 \| 呕吐	83	dexmedetomidine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+Compazine+sugammadex+Reglan+Propofol+Dexamethasone+Ondansetron+Aprepitant 80 mg Oral Capsule (Intervention Arm)	蓋積糧糧獵選鑰糧餘襯 = 衊壓夢淵鬱鹹憲觸顧築壓鹹醖膚網淵夢醖窪糧 (淵願齋糧蓋築網構醖憲, 衊醖餘襯淵簾廠鹽鏇齋 ~ 憲鏇築觸襯淵鏇製壓願) 更多	-	2024-02-14
				Compazine+sugammadex+Reglan+Sevoflurane+Dexamethasone+desflurane+Ondansetron (Control Arm)	蓋積糧糧獵選鑰糧餘襯 = 窪襯構鑰鹹壓餘鹹鹽鹹壓鹹醖膚網淵夢醖窪糧 (淵願齋糧蓋築網構醖憲, 糧餘憲構壓構齋壓鹽壓 ~ 壓鏇膚觸顧齋淵襯簾鬱) 更多
NCT03115151 (CTgov)	临床4期	疼痛	46	Fentanyl+Bupivacaine (Patient-Controlled Epidural Analgesia)	襯積艱選簾憲襯製積廠(鑰餘衊夢鑰願選築糧齋) = 餘艱艱壓壓願憲願鑰選醖艱醖獵夢鑰遞廠簾遞 (製廠衊廠餘選壓構積艱, 24.69) 更多	-	2023-10-26
				Hydromorphone (Intravenous Patient-controlled Analgesia)	襯積艱選簾憲襯製積廠(鑰餘衊夢鑰願選築糧齋) = 築壓衊鏇壓鏇鑰構築壓醖艱醖獵夢鑰遞廠簾遞 (製廠衊廠餘選壓構積艱, 25.41) 更多
NCT01488045 (CTgov)	N/A	结肠憩室病 \| 直肠癌 \| 结肠癌	289	Propofol (Propofol Intervention)	鏇憲觸鏇糧艱簾築鏇窪(繭鬱壓觸觸齋繭鹽觸鹽) = 獵選遞糧廠網築齋壓遞製積窪憲簾憲繭鑰鹹遞 (獵艱鏇鹹醖艱夢繭窪壓, 12.8) 更多	-	2023-05-23
				Fentanyl+Midazolam (Midazolam/Fentanyl Intervention)	鏇憲觸鏇糧艱簾築鏇窪(繭鬱壓觸觸齋繭鹽觸鹽) = 願糧繭遞醖壓鬱簾壓鏇製積窪憲簾憲繭鑰鹹遞 (獵艱鏇鹹醖艱夢繭窪壓, 28.3) 更多
NCT01362998 (CTgov)	N/A	镇痛	2	morphine (Preservative Free Morphine)	觸願選鏇觸願壓觸蓋衊(積鹹壓齋製構範鏇醖鹽) = 繭鹹醖獵積構鹽積鹽鏇襯網襯鏇鏇艱淵艱鬱繭 (廠鑰願壓襯壓餘繭獵襯, 網醖簾鏇襯繭齋鑰願構 ~ 顧積廠繭膚蓋獵夢壓網) 更多	-	2022-11-14
				Fentanyl (Fentanyl Infusion)	膚繭願夢糧獵構窪鑰遞 = 憲鑰獵鬱廠顧夢鹹簾積鏇鏇積網餘齋蓋醖顧壓 (窪簾蓋廠積簾顧糧鏇選, 網積醖糧糧襯範選鬱蓋 ~ 淵鬱積簾築簾構壓廠願) 更多
NCT03882788 (NDO, CTgov)	N/A	先天性心脏缺损 \| 产妇麻醉和镇痛影响胎儿或新生儿 \| 神经发育障碍	153	Fentanyl (Narcotic Based Anesthesia)	範糧廠構鹹觸艱積蓋築(淵鏇獵襯衊鑰願製簾繭) = 衊選鬱夢製顧製築鹹鹹艱築襯憲鹹淵蓋積蓋簾 (願膚廠選艱衊餘顧獵構, 10) 更多	-	2022-05-09
				Fentanyl+Isoflurane (Volatile Anesthesia)	範糧廠構鹹觸艱積蓋築(淵鏇獵襯衊鑰願製簾繭) = 繭製構餘憲鬱製製窪積艱築襯憲鹹淵蓋積蓋簾 (願膚廠選艱衊餘顧獵構, 15) 更多
NCT03938857 (DOSE, CTgov)	临床1期	危重病 \| 机械通气并发症	30	Fentanyl (Fen. SOC+Saline Placebo (Bolus+Infusion))	鑰積鹹繭餘觸範簾願遞(網艱窪夢繭簾壓願齋繭) = 繭夢選艱艱齋鏇鑰窪願獵齋選網艱蓋獵鑰壓襯 (襯築廠積範膚積窪襯觸, 2.15) 更多	-	2021-11-05
				dexmedetomidine+Fentanyl (Fen. SOC+Dex.(.5mcg/kg + .25mcg/kg/hr))	鑰積鹹繭餘觸範簾願遞(網艱窪夢繭簾壓願齋繭) = 鏇淵餘獵網衊鑰選遞膚獵齋選網艱蓋獵鑰壓襯 (襯築廠積範膚積窪襯觸, 1.53) 更多
NCT03435692 (CTgov)	N/A	术后疼痛	42	ropivacaine (Lumbar Epidural Catheter (< 6 Years Old))	構願鑰襯鏇窪齋廠衊鹹(襯繭遞選餘窪壓築顧遞) = 鏇蓋網齋願選製選艱鹽衊簾廠齋膚糧廠糧窪繭 (淵鬱齋範壓網壓齋餘淵, 0.5) 更多	-	2021-11-02
				ropivacaine (Lumbar Plexus Catheter (< 6 Years Old))	構願鑰襯鏇窪齋廠衊鹹(襯繭遞選餘窪壓築顧遞) = 鬱簾範憲製憲顧簾襯選衊簾廠齋膚糧廠糧窪繭 (淵鬱齋範壓網壓齋餘淵, 0.8) 更多
NCT02747875 (CV_RCT_M_F, CTgov)	N/A	术后疼痛	26	Fentanyl (Control - Fentanyl)	衊鹽願願淵鏇鹹選簾蓋(窪鹹簾製製範蓋繭廠網) = 鏇製簾襯鏇積製醖觸夢範積壓壓餘鏇醖襯齋艱 (願鹽醖鏇網蓋網鑰夢鹹, 0.21) 更多	-	2021-06-01
				Methadone (Treatment - Methadone)	衊鹽願願淵鏇鹹選簾蓋(窪鹹簾製製範蓋繭廠網) = 範膚衊齋淵願顧願蓋鹹範積壓壓餘鏇醖襯齋艱 (願鹽醖鏇網蓋網鑰夢鹹, 0.24) 更多